Psoriatic Arthritis

AbGn-168H Neihulizumab

Trial

Therapeutics

AbGn-168H

Trial Number

NCT# To be assigned

Disease Population

Psoriatic arthritis affects an estimated 24 in 10,000 people.
Between 5 and 10 percent of people with psoriasis develop psoriatic arthritis, according to most estimates. Some studies suggest a figure as high as 30 percent. Psoriasis itself is a common disorder, affecting approximately 2 to 3 percent of the population worldwide[1].
In the U.S., 51,200 people have psoriatic arthritis. Of these patients, 10,288 have unmet medical needs[2].
Trial Description
A pivotal trial to assess the long-term safety and clinical efficacy of Neihulizumab in treatment of moderate to severely active psoriatic arthritis
Trial Center
About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease that occurs when one’s immune system mistakenly starts attacking healthy joints (inflammatory arthritis) and skin (psoriasis).
Most people with PsA have skin symptoms before joint symptoms. However, sometimes the joint pain and stiffness strike first. About 30 percent of people with psoriasis also develop inflammatory arthritis.
The faulty immune response causes inflammation that triggers joint pain, stiffness and swelling. The inflammation can affect the entire body and may lead to permanent joint and tissue damage if it is not properly treated.
Citations
1. Genetics home reference. Psoriatic arthritis. NIH. Available at
2. IQVIA U.S. market survey with data to 2016
Details about AbGenomics Clinical Trial can be found at ClinicalTrials.gov